KTE-C19 is a therapy where some of the patient's blood cells are removed, engineered to contain a compound which targets and kills the lymphoma cells, and re-injected into the patient. It requires blood to be taken from the patient and then a single intravenous administration of treated cells, which may stay active in the body and reduce relapse.
KTE-C19 for relapsed or refractory mantle cell lymphoma
Interventions:
Axicabtagene Ciloleucel (Yescarta; KTE-C19)
Indications:
Mantle cell lymphoma
Therapeutic Areas:
Haematological Cancer and Lymphomas
Year:
2017